U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H25NO6
Molecular Weight 399.4378
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of COLCHICINE

SMILES

CC(=N[C@@]1([H])CCc2cc(c(c(c2-c3ccc(c(=O)cc31)OC)OC)OC)OC)O

InChI

InChIKey=IAKHMKGGTNLKSZ-INIZCTEOSA-N
InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1

HIDE SMILES / InChI
Colchicine is an alkaloid obtained from the plant colchicum autumnale (also known as "meadow saffron"). Colchicine is an alternative medication for those unable to tolerate NSAIDs in gout. Mechanism of action of colchicine is inhibition of microtubule polymerization by binding to tubulin. Availability of tubulin is essential to mitosis, so colchicine effectively unctions as a "mitotic poison" or spindle poison.

CNS Activity

Curator's Comment:: Known to be CNS non-penetrant in rats. Human data not available.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
COLCRYS

Approved Use

Colchicine capsules are indicated for prophylaxis of gout flares in adults. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation.

Launch Date

1.24891195E12
Primary
COLCRYS

Approved Use

Colchicine is indicated for Familial Mediterranean fever (FMF) in adults and children 4 years or older

Launch Date

1.24891195E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.68 ng/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
2.16 ng/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
2023.29 pg/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: oral
experiment type: single
co-administered:
COLCHICINE plasma
Homo sapiens
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
18.47 ng × h/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
19.9 ng × h/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
8717.33 pg*h/mL
0.6 mg single, oral
dose: 0.6 mg
route of administration: oral
experiment type: single
co-administered:
COLCHICINE plasma
Homo sapiens
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
30.54 h
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
31.04 h
0.6 mg single, oral
dose: 0.6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
COLCHICINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
61%
COLCHICINE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 42 years
n = 1
Health Status: unknown
Age Group: 42 years
Sex: M
Population Size: 1
Sources:
Other AEs: Myelosuppression...
Other AEs:
Myelosuppression (grade 4, 1 patient)
Sources:
3 mg 1 times / day multiple, oral
MTD
Dose: 3 mg, 1 times / day
Route: oral
Route: multiple
Dose: 3 mg, 1 times / day
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Other AEs: Nausea, Vomiting...
Other AEs:
Nausea (27%)
Vomiting (13%)
Diarrhea (20%)
Injection site reactions (20%)
Myalgia (27%)
Arthralgia (7%)
Allergic reaction (7%)
Sources:
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
unknown, 56 years
n = 1
Health Status: unknown
Age Group: 56 years
Sex: M
Population Size: 1
Sources:
Other AEs: Rhabdomyolysis...
Other AEs:
Rhabdomyolysis (grade 5, 1 patient)
Sources:
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Acute pancreatitis, Epigastric pain...
AEs leading to
discontinuation/dose reduction:
Acute pancreatitis (1 patient)
Epigastric pain (severe, 1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Sources:
0.6 mg 2 times / day multiple, oral
Dose: 0.6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.6 mg, 2 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: Thoracic Surgery
Population Size: 49
Sources:
Other AEs: Acute respiratory distress syndrome, Fall...
Other AEs:
Acute respiratory distress syndrome (serious, 3 patients)
Fall (serious, 2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Myelosuppression grade 4, 1 patient
50 mg single, oral
Overdose
Dose: 50 mg
Route: oral
Route: single
Dose: 50 mg
Sources:
unknown, 42 years
n = 1
Health Status: unknown
Age Group: 42 years
Sex: M
Population Size: 1
Sources:
Vomiting 13%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Diarrhea 20%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Injection site reactions 20%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Myalgia 27%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Nausea 27%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Allergic reaction 7%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Arthralgia 7%
1 mg 1 times / week multiple, intravenous
Dose: 1 mg, 1 times / week
Route: intravenous
Route: multiple
Dose: 1 mg, 1 times / week
Sources:
unhealthy, 44 years (range: 39.5–48.5 years)
n = 15
Health Status: unhealthy
Condition: familial Mediterranean fever
Age Group: 44 years (range: 39.5–48.5 years)
Sex: M+F
Population Size: 15
Sources:
Rhabdomyolysis grade 5, 1 patient
12 mg single, oral
Overdose
Dose: 12 mg
Route: oral
Route: single
Dose: 12 mg
Sources:
unknown, 56 years
n = 1
Health Status: unknown
Age Group: 56 years
Sex: M
Population Size: 1
Sources:
Acute pancreatitis 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Nausea 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Vomiting 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Epigastric pain severe, 1 patient
Disc. AE
1 mg 1 times / day multiple, oral
Recommended
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy, 79 years
n = 1
Health Status: unhealthy
Age Group: 79 years
Sex: M
Population Size: 1
Sources:
Fall serious, 2 patients
0.6 mg 2 times / day multiple, oral
Dose: 0.6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.6 mg, 2 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: Thoracic Surgery
Population Size: 49
Sources:
Acute respiratory distress syndrome serious, 3 patients
0.6 mg 2 times / day multiple, oral
Dose: 0.6 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.6 mg, 2 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: Thoracic Surgery
Population Size: 49
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
yes
likely (co-administration study)
Comment: Although there are no published case reports for colchicine toxicity when co-administered with the 4 inhibitors that the sponsor employed, i.e., voriconazole, fluconazole, cimetidine and propafenone, several published case reports indicate that colchicine toxicity is observed when it is co-administered with drugs that are potent inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin, ketoconazole) as well as potent P-gp inhibitors (e.g., cyclosporine).
Page: 2.0
yes
yes (co-administration study)
Comment: Co-administration with posaconazole (considered a strong CYP3A4 inhibitor) increased AUC of colchcine by approximately 3-fold; Although there are no published case reports for colchicine toxicity when co-administered with the 4 inhibitors that the sponsor employed, i.e., voriconazole, fluconazole, cimetidine and propafenone, several published case reports indicate that colchicine toxicity is observed when it is co-administered with drugs that are potent inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin, ketoconazole) and strong to moderate inhibitors of CYP3A4 (e.g., grapefruit juice, erythromycin).
Page: 2.0
PubMed

PubMed

TitleDatePubMed
Colchicine-induced lesions in the rat duodenum.
1975
Evaluation of natural products as inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase.
1991 Jan-Feb
Colchicine myopathy in a case of familial Mediterranean fever: immunohistochemical and ultrastructural study of accumulated tubulin-immunoreactive material.
1992
Serum interleukin-2 and tumor necrosis factor-alpha in primary biliary cirrhosis: decrease by colchicine and relationship to HLA-DR4.
1992 Apr
Colchicine-induced myoneuropathy in a renal transplant patient.
1992 Jun
[Treatment of AL-amyloidosis and some other types of amyloidosis].
2001 Jan
Abstracts of the Fourth International Symposium on Molecular Insect Science. May 28-June 2, 2002. Tucson, Arizona, USA.
2002
[Neurotoxic effects of medications: an update].
2004
Microtubule disarray in primary cultures of human hepatocytes inhibits transcriptional activity of the glucocorticoid receptor via activation of c-jun N-terminal kinase.
2004 Dec
Colchicine myotoxicity: case reports and literature review.
2004 Dec
Cytoskeletal myotoxicity from simvastatin and colchicine.
2004 Dec
Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance.
2004 Dec
RLIP76 (RALBP1)-mediated transport of leukotriene C4 (LTC4) in cancer cells: implications in drug resistance.
2004 Dec 20
[Abdominal pain and recurrent cholestatic jaundice].
2004 Jun 9
Acute poisoning with autumn crocus (Colchicum autumnale L.).
2004 Mar 31
Myelodysplasia and acute myeloid leukaemia in a case of rheumatoid arthritis with secondary amyloidosis treated with chlorambucil.
2004 May
Establishment of a P-glycoprotein substrate screening model and its preliminary application.
2004 May 1
[Experimental study on Sorbaria sorbifolia extract against chronic liver damage in rats].
2004 Oct
Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
2004 Oct 1
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats.
2004 Sep
RhoA/ROCK and Cdc42 regulate cell-cell contact and N-cadherin protein level during neurodetermination of P19 embryonal stem cells.
2004 Sep 5
Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium.
2005
Monozygotic twins concordant for intestinal Behçet's disease.
2005 Apr
[Acute coronary syndrome after diclofenac induced coronary spasm].
2005 Apr
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1.
2005 Apr
Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study.
2005 Aug 1
Induction of resistance to Aplidin in a human ovarian cancer cell line related to MDR expression.
2005 Dec
Acute myopathy in a patient with concomitant use of pravastatin and colchicine.
2005 Jul-Aug
Chromosomal aberrations in lymphocytes of healthy subjects and risk of cancer.
2005 May
Acute renal failure associated with an accidental overdose of colchicine.
2005 Oct
[Nephrogenic diabetes insipidus induced by colchicine--a case report].
2005 Sep
[A case report of acute neuromyopathy induced by concomitant use of colchicine and bezafibrate].
2005 Sep
Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood-brain barrier.
2005 Sep 17
An unusual cause of renal amyloidosis secondary to gout: the first description of familial occurrence.
2006
Expression of corticosterone-binding globulin in the rat hypothalamus.
2006 Apr
Colchicine myoneuropathy in chronic renal failure patients with gout.
2006 Apr
Involvement of cytoskeleton in AhR-dependent CYP1A1 expression.
2006 Apr
Preplaced cell division: a critical mechanism of autoprotection against S-1,2-dichlorovinyl-L-cysteine-induced acute renal failure and death in mice.
2006 Aug
Colchicine and HMG Co-A reductase inhibitors induced myopathy-a case report.
2006 Dec
Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay.
2006 Dec 1
Colchicine therapy and the cognitive status of elderly patients with familial Mediterranean fever.
2006 Jul
Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression.
2006 Jul 26
[Effect of the ethyl acetate extract of zhi ju zi on serum makers and the expression of TGF-beta1 in rats with hepatic fibrosis].
2006 Jun
Sweet's syndrome from an Indian perspective: a report of four cases and review of the literature.
2006 Jun
A role for mixed lineage kinases in granule cell apoptosis induced by cytoskeletal disruption.
2006 Mar
Synthesis and biological evaluation of B-ring modified colchicine and isocolchicine analogs.
2006 May 15
Cyclosporine not the only agent to cause Guillain-Barré-like syndrome after solid-organ transplant.
2006 Nov
Microtubules are required for NF-kappaB nuclear translocation in neuroblastoma IMR-32 cells: modulation by zinc.
2006 Oct
Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats.
2007
Zinc and the cytoskeleton in the neuronal modulation of transcription factor NFAT.
2007 Jan
Patents

Sample Use Guides

In Vivo Use Guide
For prophylaxis of gout flares, the recommended dosage of Colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals.
Route of Administration: Oral
In Vitro Use Guide
Inhibition of the polymerization of brain tubulin was evaluated. Solution of compound in DMSO in serial dilutions was prepared. Reaction mixture contained 0.25 mg of tubulin, 1.0 M monosodium glutamate and approptiate drug concentrations. The reaction mixtures were incubated at 37 °C for 15 min to allow slow binding drugs like colchicine to bind to the tubulin. The reaction mixtures were then chilled on ice, and the polymerization reaction was followed turbidimetrically for 20 min. Polymer formation was confirmed by evaluation of depolymerization at 0°C. Extent of inhibition of polymerization at 20 min in drug-treated samples was always calculated by comparing them to a pair of drug-free samples in each experimental set.
Name Type Language
COLCHICINE
EP   HSDB   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
Common Name English
NSC-757
Code English
COLCHICINUM
HPUS   WHO-IP LATIN  
Common Name English
ACETAMIDE, N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO(A)HEPTALEN-7-YL)-,(S)-
Common Name English
COLCHICINE COMPONENT OF PROBEN-C
Common Name English
COLCHICINE [WHO-IP]
Common Name English
(S)-N-(5,6,7,9-TETRAHYDRO-1,2,3,10-TETRAMETHOXY-9-OXOBENZO(A)HEPTALEN-7-YL)ACETAMIDE
Systematic Name English
COLBENEMID COMPONENT COLCHICINE
Common Name English
COLCHICINE COMPONENT OF COLBENEMID
Common Name English
COLCHICINE COMPONENT OF COL-PROBENECID
Common Name English
COLCHICINE [USP]
Common Name English
COLCHICINE [USP-RS]
Common Name English
COLCHCINE [VANDF]
Common Name English
COLCHICINE [WHO-DD]
Common Name English
COLCHICINE [EP]
Common Name English
GLOPERBA
Brand Name English
(-)-COLCHICINE
Common Name English
MITIGARE COMPONENT COLCHICINE
Brand Name English
PROBEN-C COMPONENT COLCHICINE
Common Name English
COLCHICINUM [WHO-IP LATIN]
Common Name English
COLCRYS
Brand Name English
COLCHINEOS
Common Name English
COLCHICINE [ORANGE BOOK]
Common Name English
COLCHICINE COMPONENT OF MITIGARE
Brand Name English
COLCHICINE [MI]
Common Name English
COLCHICINUM [HPUS]
Common Name English
COLCHICINE [EP MONOGRAPH]
Common Name English
COLCHICINE [JAN]
Common Name English
COLCHICINE [MART.]
Common Name English
COL-PROBENECID COMPONENT COLCHICINE
Common Name English
COLCHISOL
Common Name English
COLCHICINE [HSDB]
Common Name English
Classification Tree Code System Code
WHO-VATC QM04AC01
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
FDA ORPHAN DRUG 11085
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
FDA ORPHAN DRUG 245707
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
FDA ORPHAN DRUG 245807
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
NCI_THESAURUS C67421
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
WHO-ATC M04AC01
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
LIVERTOX 234
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
200-598-5
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
HSDB
3044
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
COLCHICINE
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY Description: Pale yellow to pale greenish yellow crystals, amorphous scales or a powder; odourless or almost odourless.Solubility: Soluble in water; freely soluble in ethanol (~750 g/l) TS; slightly soluble in ether R.Category: Antigout drug.Storage: Colchicine should be kept in a tightly closed container, protected from light.Additional information: Colchicine is an alkaloid obtained from Colchicum autumnale L. (Fam. Liliaceae). It darkens on exposureto light. CAUTION: Colchicine is extremely poisonous and must be handled with care.
LACTMED
Colchicine
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
MERCK INDEX
M3725
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY Merck Index
FDA UNII
SML2Y3J35T
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
MESH
D003078
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
ChEMBL
CHEMBL107
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
PUBCHEM
6167
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
NDF-RT
N0000000239
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY P-Glycoprotein Interactions [MoA]
NDF-RT
N0000182141
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
CAS
64-86-8
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
NCI_THESAURUS
C385
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
EPA CompTox
64-86-8
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
DRUG CENTRAL
726
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
IUPHAR
2367
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
RXCUI
2683
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY RxNorm
WIKIPEDIA
COLCHICINE
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
EVMPD
SUB01420MIG
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
DRUG BANK
DB01394
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY
USP_CATALOG
1146006
Created by admin on Fri Jun 25 21:16:51 UTC 2021 , Edited by admin on Fri Jun 25 21:16:51 UTC 2021
PRIMARY USP-RS